Spotlight On... Pfizer teams with Silicon Valley incubator to promote consumer health startups; FDA clears Optovue's AngioVue retinal imaging; J&J hit with $13.5M pelvic mesh verdict; and more...

Pfizer Consumer Healthcare ($PFE) announced the launch of joint health and wellness innovation program that will enable 10 med tech startups to utilize the San Francisco office of tech industry incubator Galvanize. The duo is accepting applications for new companies focused on improving sleep, stress management, energy, aging and nutrition. "We're excited to team up with a leader in healthcare such as Pfizer Consumer Healthcare to foster innovation in the health and tech industry," said Galvanize CEO and co-founder, Jim Deters. "This program will provide an amazing environment for healthcare startups to grow and reach their full potential, and is proof of Galvanize's ability to provide great technical talent and invaluable resources for founders." The winning companies will have access to Galvanize's programming as well its network of possible investors. In addition, they can receive mentoring from the minds at Pfizer Consumer Healthcare. "Developing new ways for consumers to improve their health and well-being remains a priority for Pfizer Consumer Healthcare," said Suneet Varma, the president and general manager of Pfizer Consumer Healthcare. "Collaborating with new partners enables us to build on our own efforts to develop new, innovative ways for consumers to achieve better health and wellness by tapping into the creativity and thinking taking place all around us." Release | Website

@FierceMedDev: Scilex aims to dethrone Endo in billion-dollar pain subsegment using novel transdermal patch. FierceDrugDelivery story | Follow @FierceMedDev

@EmilyWFierce: Big Pharma shells out big campaign dollars to presidential candidates. FiercePharma article | Follow @EmilyWFierce

> The FDA has cleared Optovue's AngioVue Imaging System to offer noninvasive imaging to detect abnormal blood vessels in the retina. More

> Anthem, the largest member of the Blue Cross Blue Shield Association that covers 38.5 million people, said that is will cover Novocure's ($NVCR) Optune to treat newly diagnosed glioblastoma (GBM). More

> A Philadelphia jury has awarded a woman $13.5 million from Johnson & Johnson ($JNJ) who had claimed injury by pelvic mesh from its Ethicon business. More

Biotech News

@FierceBiotech: Novartis buys EU rights to Pfizer's Remicade biosimilar, targeting Merck. Report | Follow @FierceBiotech

@JohnCFierce: Google cool: I spend no time fundraising," Maris tells . "Alphabet can give us as much $$ as we want. More from Bloomberg | Follow @JohnCFierce

@DamianFierce: Early theme in responses to this poll: Men much more likely to get "stretch" jobs, be lauded for ambitious failures. ICYMI from FierceBiotech | Follow @DamianFierce

> Alnylam bets $200M on its commercial future with new plant. News

> U.K.'s Shield pulls off an IPO but dramatically cuts its flotation price. Article

> Apellis raises $47M after pulling the plug on an $86M IPO. Report

Pharma News

@FiercePharma: Startup aims to match ailing pets with clinical trials that could help people, too. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Qualicaps snags Brazil's largest hard capsule maker. Will expand in Latin America from there. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Teva's Copaxone finally succumbs to copycats, putting a drag on 2015 sales. Article | Follow @CarlyHFierce

> AstraZeneca and Daiichi Sankyo field backlash over Super Bowl OIC awareness ad. Story

> Burwell says HHS is considering 'march-in' on skyrocketing drug prices. Article

> Lilly suffers stinging defeat in EU patent battle over Alimta. Report